New biomarkers, such as DM‐specific autoantibodies (anti‐Mi‐2, anti‐MDA5, anti‐TIF‐1γ, anti‐NXP2, and anti‐SAE) correlate with distinct clinical phenotypes with respect to organ involvement and malignancy in cancer‐associated myositis (CAM, (4)). The gene discussed is TRIM33; the disease is dermatomyositis.